Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Contributed by: Business Wire

Logo

Tags

Technology

Research

Clinical Trials

Biotechnology

Health

Pharmaceutical

General Health

Science

Artificial Intelligence

Biocytogen

More Like This

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano）

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development